Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer

Journal of Clinical Oncology

Volumn 29, Issue 36, 2011, Pages 4789-4795

  Graziano, Francesco ^a   Galluccio, Nadia ^b   Lorenzini, Paola ^a   Ruzzo, Annamaria ^b   Canestrari, Emanuele ^b   D'Emidio, Silvia ^a   Catalano, Vincenzo ^a   Sisti, Valerio ^a   Ligorio, Claudia ^c   Andreoni, Francesca ^b   Rulli, Eliana ^d   Di Oto, Enrico ^c   Fiorentini, Giammaria ^a   Zingaretti, Costantino ^a   De Nictolis, Michele ^a   Cappuzzo, Federico ^e   Magnani, Mauro ^b  

^a Azienda Ospedaliera Ospedali Riuniti Marche Nord   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c Malpighi Hospital   (Italy)

^d Istituto di Ricerche Farmacologiche Mario Negri   (United States)

^e Livorno Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; SCATTER FACTOR RECEPTOR;

AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER GAIN; DEOXYADENOSINE TRACT ELEMENT; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE ACTIVATION; GENE DOSAGE; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER;

ADULT; AGED; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HEPATOCYTE GROWTH FACTOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RISK; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84555202718     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.7706     Document Type: Article

References (26)

1. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
2. Arkenau H: Gastric cancer in the era of molecularly targeted agents: Current drug development strategies. J Cancer Res Clin Oncol 135:855-866, 2009
3. Huang TJ, Wang JY, Lin SR, et al.: Overexpression of the c-met protooncogene in human gastric carcinoma: Correlation to clinical features. Acta Oncol 40:638-643, 2001
4. Wu CW, Li AF, Chi CW, et al.: Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5:817-822, 1998 (Pubitemid 28270673)
5. Inoue T, Kataoka H, Goto K, et al.: Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 95:803-808, 2004 (Pubitemid 39545586)
6. Nakajima M, Sawada H, Yamada Y, et al.: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894-1902, 1999 (Pubitemid 29202761)
7. Trusolino L, Bertotti A, Comoglio PM: MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834-848, 2010
8. Park WS, Oh RR, Kim YS, et al.: Absence of mutations in the kinase domain of the MET gene and frequent expression of MET and HGF/SF protein in primary gastric carcinomas. APMIS 108:195-200, 2000 (Pubitemid 30158999)
9. Hara T, Ooi A, Kobayashi M, et al.: Amplification of c-myc, K-sam, and c-MET in gastric cancers: Detection by fluorescence in situ hybridization. Lab Invest 78:1143-1153, 1998 (Pubitemid 28440830)
10. Tsugawa K, Yonemura Y, Hirono Y, et al.: Amplification of the c-MET, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: Correlation to clinical features. Oncology 55: 475-481, 1998 (Pubitemid 28396062)
11. Ma J, Defrances MC, Zou C, et al.: Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 119:478-491, 2009
12. Cappuzzo F, Marchetti A, Skokan M, et al.: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667-1674, 2009
13. Porter J: Small molecule c-Met kinase inhibitors: A review of recent patents. Expert Opin Ther Pat 20:159-177, 2010
14. Aten E, White SJ, Kalf ME, et al.: Methods to detect CNVs in the human genome. Cytogenet Genome Res 123:313-321, 2008
15. Mallett S, Timmer A, Sauerbrei W, et al.: Reporting of prognostic studies of tumour markers: A review of published articles in relation to REMARK guidelines. Br J Cancer 102:173-180, 2010
16. Müller R, Büttner P: A critical discussion of intraclass correlation coefficients. Stat Med 13:2465-2476, 1994
17. Lu L, Shara N: Reliability analysis: Calculate and compare intra-class correlation coefficients (ICC) in SAS. 20th Northeast SAS Users Group 2007 Conference Proceedings, Baltimore, MD, November 11-14, 2007. www.nesug.org/proceedings/nesug07/sa/sa13.pdf
18. Lee J, Seo JW, Jun HJ, et al.: Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517-1524, 2011
19. Janjigian YY, Tang LH, Coit DG, et al.: MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20:1021-1027, 2011
20. Dua R, Zhang J, Parry G, et al.: Detection of hepatocyte growth factor (HGF)ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay. PLoS One 6:e15932, 2011
21. Park M, Park H, Kim WH, et al.: Presence of autocrine hepatocyte growth factor-Met signaling and its role in proliferation and migration of SNU-484 gastric cancer cell line. Exp Mol Med 37:213-219, 2005 (Pubitemid 40992737)
22. Jones SF, Cohen RB, Bendell JC, et al.: Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced non-hematologic malignancies: First-in-human phase I dose-escalation study. J Clin Oncol 28:253s, 2010 (suppl, abstr 3081)
23. Patnaik A, Weiss GJ, Papadopoulos K, et al.: Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 28:210s, 2010 (suppl, abstr 2525)
24. Hartgrink HH, Jansen EP, van Grieken NC, et al.: Gastric cancer. Lancet 374:477-490, 2009
25. Yap TA, Olmos D, Brunetto AT, et al.: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271-1279, 2011
26. Smolen GA, Sordella R, Muir B, et al.: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103:2316-2321, 2006